Oct 24, 2022
|
Ardelyx to Present Poster Presentations on IBSRELA® (tenapanor) for Adult Patients with IBS-C at the American College of Gastroenterology 2022 Annual Scientific Meeting
|
Oct 20, 2022
|
Ardelyx Announces Poster Presentations on XPHOZAH® (tenapanor) at ASN's Kidney Week 2022
|
Sep 30, 2022
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
Sep 6, 2022
|
Ardelyx to Participate in Upcoming Investor Conferences
|
Aug 4, 2022
|
Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights
|
Aug 2, 2022
|
Ardelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference
|
Jul 28, 2022
|
Ardelyx to Report Second Quarter 2022 Financial Results on August 4, 2022
|
Jul 1, 2022
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
Jun 30, 2022
|
Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners
|
Jun 21, 2022
|
Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022
|